Ecopipam Does Not Adversely Affect Metabolic Parameters in Pediatric Patients With Tourette Syndrome (TS): Results From a Phase 2b Randomized, Placebo-Controlled Trial (RCT) With a 12-Month Open-Label Extension (OLE)

被引：0
|
作者：
Gilbert, D. L.
Atkinson, S. D.
Karkanias, G. B.
Munschauer, F.
Wanaski, S.
Cunniff, T.
机构：
来源：
ANNALS OF NEUROLOGY | 2025年 / 96卷
关键词：
Experimental Therapeutics; Movement Disorders;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
96
引用
收藏
页码：S62 / S62
页数：1
相关论文
共 50 条
  • [1] Ecopipam does not adversely affect Metabolic Parameters in Pediatric Subjects with Tourette Syndrome: Results from a Phase 2b with 12-month Open Label Extension Study
    Gilbert, D.
    Atkinson, S.
    Karkanias, G.
    Munschauer, F.
    Wanaski, S.
    Cunniff, T.
    MOVEMENT DISORDERS, 2024, 39 : S292 - S292
  • [2] Long-term safety and durability of effect of ecopipam in pediatric patients with Tourette Syndrome: Results of a 12-month open-label extension (OLE) study
    Gilbert, D.
    Kim, D.
    Miller, M.
    Horine, S.
    Saljooqi, K.
    Karkanias, G.
    Wanaski, S.
    Cunniff, T.
    MOVEMENT DISORDERS, 2023, 38 : S421 - S421
  • [3] Long-term safety and durability of effect of ecopipam in pediatric patients with Tourette Syndrome: Results of a 12-month open-label extension (OLE) study
    Gilbert, D.
    Kim, D.
    Miller, M.
    Horine, S.
    Saljooqi, K.
    Karkanias, G.
    Wanaski, S.
    Cunniff, T.
    ANNALS OF NEUROLOGY, 2023, 94 : S85 - S85
  • [4] Efficacy and Tolerability of Elamipretide in Patients With Barth Syndrome: Results From Tazpower, a Randomized, Double-Blind, Placebo-Controlled, Crossover and Open-Label Extension Trial
    Vernon, Hilary J.
    Thompson, WIlliam R.
    Aiudi, Anthony
    Jones, John J.
    Carr, Jim
    Hornby, Brittany DeCroes
    CIRCULATION, 2019, 140
  • [5] Effect of Ecopipam, a Selective Dopamine-1 Receptor Antagonist, on Tic Characteristics as Assessed by the YGTSS: Results From the Phase 2b Randomized, Double-blind, Placebo-controlled Clinical Trial in Tourette Syndrome
    Gilbert, D. L.
    Karkanias, G. B.
    Atkinson, S. D.
    Munschauer, F.
    Wanaski, S.
    Cunniff, T.
    ANNALS OF NEUROLOGY, 2025, 96 : S62 - S63
  • [6] LONG-TERM TREATMENT WITH TRANSDERMAL ROTIGOTINE IN PATIENTS WITH IDIOPATHIC RESTLESS LEGS SYNDROME (RLS): RESULTS FROM A 12-MONTH OPEN-LABEL EXTENSION TRIAL
    Allen, R. P.
    Winkelman, J.
    Ondo, W.
    Fichtner, A.
    Schollmayer, E.
    SLEEP, 2010, 33 : A251 - A251
  • [7] CARDIOVASCULAR SAFETY OF DEGARELIX: RESULTS FROM A 12-MONTH, COMPARATIVE, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP PHASE III TRIAL IN PROSTATE CANCER PATIENTS
    Klotz, Laurence
    Smith, Matthew
    Persson, Bo-Eric
    Olesen, Tine Kold
    Wilde, Arthur
    JOURNAL OF UROLOGY, 2010, 183 (04): : E228 - E228
  • [8] Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial
    Distler, Oliver
    Allanore, Yannick
    Denton, Christopher P.
    Kuwana, Masataka
    Matucci-Cerinic, Marco
    Pope, Janet E.
    Atsumi, Tatsuya
    Becvar, Radim
    Czirjak, Laszlo
    Hachulla, Eric
    Ishii, Tomonori
    Ishikawa, Osamu
    Johnson, Sindhu R.
    De Langhe, Ellen
    Stagnaro, Chiara
    Riccieri, Valeria
    Schiopu, Elena
    Silver, Richard M.
    Smith, Vanessa
    Steen, Virginia
    Stevens, Wendy
    Szuecs, Gabriella
    Truchetet, Marie-Elise
    Wosnitza, Melanie
    Laapas, Kaisa
    Kramer, Frank
    Khanna, Dinesh
    LANCET RHEUMATOLOGY, 2023, 5 (11): : E660 - E669
  • [9] Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study
    Takashi Wada
    Masaya Inagaki
    Toru Yoshinari
    Ryuji Terata
    Naoko Totsuka
    Miki Gotou
    Gaia Hashimoto
    Clinical and Experimental Nephrology, 2021, 25 : 120 - 130
  • [10] Elamipretide (ELAM) in Subjects With Barth Syndrome (TAZPOWER): A Phase 2 Randomized, Double-Blind, Placebo-Controlled Crossover Trial Followed by an Open-Label Treatment Extension
    Vernon, Hilary J.
    Thompson, William Reid
    Hornby, Brittany
    CIRCULATION, 2018, 138
12345